AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 151 min read$INBX

MANHARD KIMBERLY sold $164K of INBX (indirect holdings)

MANHARD KIMBERLY sold 1,500 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $109.03 ($105.05–$111.78, $0.16M total) across 3 trades over 2026-09-11 to 2026-09-15.

Original reporting
SEC EDGAR · MANHARD KIMBERLY
Published Sep 15, 2026, 9:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 9:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INBX
Neutral
high confidence
Mentioned
$INBX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INBXNeutralLow
01

Why it matters

The sale is small and unlikely to affect INBX's valuation, but it provides transparency for investors monitoring insider activity.

02

Market read

Limited relevance; primarily of interest to insider-tracking investors.

03

What to watch

Potential upcoming clinical trial results or financing events not disclosed in the filing.

Relevance 4/10Novelty 4/10Timing: filed Sep 15 2026

Background

Form 4 filings disclose insider transactions; they are primary disclosures required by the SEC.

Company-level read

Ticker impact

$INBXNeutralHigh confidence
Context

Director Manhard Kimberly sold 1,500 shares for $163,542.50 via open-market transactions.

Expected impact

Minimal short-term price pressure; unlikely to move the stock materially.

Evidence & confidence

The filing is a primary source (Form 4) and the transaction size ($163k) is trivial for a listed biotech, so market impact is expected to be negligible.

Market effects

Sector

No broader sector impact; insider sales are routine.

Regional

None

Global

None

Counterpoint

What could challenge this read

If the director holds a larger stake, the sale could be a tactical liquidity move rather than a lack of confidence.

Key entities

  • Director
    Manhard Kimberly

    Director of Inhibrx Biosciences who sold shares.

  • Company
    Inhibrx Biosciences, Inc.

    Biotech firm listed on NASDAQ under ticker INBX.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INBX insider trading history →

Related articles

SEP 8
$INBXMedAI 8/10

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

Inhibrx Biosciences (INBX) reported positive Phase 2 trial results for INBRX-106 combined with pembrolizumab in head and neck cancer. The combination showed a 48.3% response rate vs 26.5% for pembrolizumab alone, with 9.6-month median PFS. HPV+ patients saw even stronger results. The company plans to expand the trial and explore further applications. INBRX-106 is a hexavalent OX40 agonist.

prnewswire.com2 min
SEP 8
$INBXHighAI 8/10

Inhibrx stock jumps on positive cancer drug trial results

Inhibrx Biosciences (NASDAQ:INBX) shares rose 6% after reporting positive Phase 2 trial results for INBRX-106 combined with pembrolizumab in head and neck cancer. The combination showed a 48.3% response rate vs. 26.5% for pembrolizumab alone. The study included 63 patients, with notable improvements in HPV-positive patients. The company plans to expand the trial and align with the FDA for a potential accelerated pathway.

investing.com2 min
AUG 13
$INBXMedAI 8/10

Inhibrx Reports Second Quarter 2026 Financial Results

Inhibrx Biosciences (Nasdaq: INBX) reported Q2 2026 results. It received $100.0 million from Oxford Finance under a loan amendment that allows up to $325.0 million gross proceeds. Cash rose to $219.5 million as of Aug. 6. Q2 R&D was $23.9 million, net loss $36.7 million ($2.34/share). FDA accepted its ozekibart BLA with PDUFA April 14, 2027.

prnewswire.com4 min
AUG 13
$INBXMed

Inhibrx Biosciences, Inc. (INBX): Results of Operations and Financial Condition

Inhibrx Biosciences, Inc. (INBX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inhibrx Reports Second Quarter 2026 Financial Results San Diego, CA, August 13, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the second quarter of 2026. The biopharmaceutical company has two program

SEC EDGAR 8-K6 min
AUG 13
$INBXMedAI 8/10

FDA Sets April 2027 Goal Date for Inhibrx's Ozekibart

Inhibrx Biosciences (Nasdaq: INBX) reported Q2 2026 results and said the FDA accepted its BLA for ozekibart (INBRX-109) in conventional chondrosarcoma, assigning a PDUFA goal date of April 14, 2027. The company also amended its Oxford Finance loan for up to $325.0 million. Q2 net loss was $36.7 million; cash was $219.5 million as of Aug. 6, 2026.

stocktitan.net4 min